Despite the variability in infection and therapeutic success within the allografts, intratumoral injections with talimogene laherparepvec (T-VEC, a modified HSV-1 OV that is currently approved for treating unresectable melanoma) increased the infiltration of CD4+ and CD8+ T cells in all allografts. This evidence concerns the gene CD8A and melanoma.